Noel Clarke has been a Consultant Urological Surgeon at the Christie and Salford Royal Hospitals, Manchester, UK since 1993, and Honorary Professor of Urological Oncology at Manchester University, Manchester, UK since 2007. He completed his MBBS in London, UK in 1981, his FRCS(Eng) in 1985, his ChM in Manchester 1990 and his urological accreditation and FRCS(Urol) in 1991. Since that time he has specialised in secondary and tertiary referral complex pelvic and retroperitoneal surgery, research in to genito-urinary (GU) malignancy and the delivery of cancer treatment in health care systems. He is a nationally and internationally recognised expert in the diagnosis and treatment of cancers of the prostate, bladder, kidney and testis in addition to providing UK regional and supra-regional surgical provision for complex and rare abdomino-pelvic tumours.
Professor Clarke has held the positions of Director of Urology at Salford Royal Hospitals and Director of Surgery at the Christie Hospital, served 2 terms on the British Association of Urological Surgeons (BAUS) executive committee and was one of the founding group members involved in developing the BAUS section of oncology. He was one of two urologists involved in the development and publication of the “Improving Outcomes Guidance”, a plan for delivery of urological cancer care in England from 2002 to 2005 and he Chaired the Manchester and Cheshire Urological Cancer Network between 2002 and 2010.
In research, he was Chairman of the UK National Cancer Research Institute Prostate Clinical Studies Group between 2003 and 2009, was integrally involved in the development of the STAMPEDE, RADICALS and PATCH trials, and Co-Chaired the European Organisation for Research and Treatment of Cancer GU group. He is currently Director of the Manchester University GU Cancer Research Group, the pan-Manchester biobank and clinical lead for the Manchester/Belfast FASTMAN national centre of excellence for prostate cancer research. He is the joint clinical lead and BAUS representative for the National Prostate Cancer Audit in England and Wales. He is a co-Principal Investigator of the STAMPEDE, RADICALS and PROpel trials and has been involved extensively in national and international cancer trial planning, coordination and data analysis, including the IceCaP and StopCaP initiatives. Professor Clarke’s research interests encompass basic/translational science and Phase I, II, and III trials in urological cancer. He has authored 277 peer-reviewed papers and 9 book chapters on urology and urological cancer during the course of supervising/training >30 PhD/MD students from a wide range of medical and scientific disciplines.
EM-112767 - Date of preparation: October 2022